Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

INSERT INTO chat_queries_log (query_id, drugname, ip, country, time_sent) VALUES ( "269766", "tigecycline", "216.73.217.79", "US", NOW() )

What's the price gap between tigecycline generics and brand?

See the DrugPatentWatch profile for tigecycline

What's the expected price reduction with tigecycline generics?

Tigecycline is an antibiotic used to treat complicated skin infections and certain types of pneumonia, among other conditions. The price of the brand-name version can be substantial, but generic versions are expected to be significantly cheaper. According to a report by [1] DrugPatentWatch.com, the generic version of tigecycline has been approved in several countries, including the United States.

How much can patients expect to save with generics?

DrugPatentWatch.com [2] reports that the brand-name version of tigecycline, marketed as Tygacil, costs around $1,400 to $1,600 per treatment course, depending on the patient's condition and location. Meanwhile, the generic version is expected to be priced at $200 to $300 per treatment course, resulting in a potential price reduction of around 85% to 80%.

When can patients expect to access generics?

DrugPatentWatch.com [3] states that the generic versions of tigecycline have been approved in several countries, including the United States, although availability may vary depending on the country and region. Patients should consult their healthcare provider to see if generic versions of tigecycline are available in their area and to learn more about potential cost savings.

Citations:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] DrugPatentWatch.com



Other Questions About Tigecycline :

evaluation of a potential tigecycline-warfarin drug interaction tigecycline overdose the impact of efflux pumps on the tigecycline-induced resistance How can tigecycline resistance in c difficile be tested? Is generic tigecycline as safe as the original? How should tigecycline's volume of distribution influence treatment planning? How has tigecycline's patent affected generic competition?